Botulinum Toxin Market Research Report Information By Product (Botulinum Toxin A and Botulinum Toxin B), By Application (Medical and Aesthetic), By Gender (Female and Male), By Age Group (13-19, 20-29, 30-39, 40-54, and 55 & Above), By End User (Hospitals, Dermatology Clinics, and Spas & Cosmetic Centers) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2032

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 16

1.1.1 MARKET SYPNOSIS 16

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 17

2.2 RESEARCH OBJECTIVE 17

2.3 LIST OF ASSUMPTIONS 17

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 19

3.2 DATA MINING 19

3.3 SECONDARY RESEARCH 20

3.4 PRIMARY RESEARCH 21

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 22

3.5 BREAKDOWN OF PRIMARY RESPONDENTS 23

3.6 FORECASTING METHODS 24

3.7 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25

3.7.1 BOTTOM-UP APPROACH 26

3.7.2 TOP-DOWN APPROACH 26

3.8 DATA TRIANGULATION 27

3.9 VALIDATION 27

4 MARKET DYNAMICS

4.1 OVERVIEW 28

4.2 DRIVERS 29

4.2.1 RISING CASES OF SPASTICITY, CERVICAL DYSTONIA, AND CHRONIC MIGRAINE 29

4.2.2 GROWING DEMAND FOR FACIAL AESTHETICS 29

4.2.3 INCREASING PRODUCT LAUNCHES AND APPROVALS 30

4.3 RESTRAINTS 31

4.3.1 ADVERSE EFFECTS ASSOCIATED WITH BOTULINUM TOXIN 31

4.3.2 POOR REIMBURSEMENT POLICIES 32

4.4 OPPORTUNITIES 33

5 MARKET FACTOR ANALYSIS

5.1 PORTERS FIVE FORCES 34

5.1.1 THREAT OF NEW ENTRANTS 35

5.1.2 BARGAINING POWER OF SUPPLIERS 35

5.1.3 THREAT OF SUBSTITUTES 35

5.1.4 BARGAINING POWER OF BUYERS 35

5.1.5 INTENSITY OF RIVALRY 35

5.2 VALUE CHAIN ANALYSIS 36

5.2.1 RESEARCH AND DEVELOPMENT 36

5.2.2 MANUFACTURING PROCESS OF BOTULINUM TOXIN 37

5.2.3 MARKETING AND DISTRIBUTION 37

6 BOTULINUM TOXIN MARKET, BY TYPE

6.1 INTRODUCTION 38

6.2 BOTULINUM TOXIN TYPE A 39

6.3 BOTULINUM TOXIN TYPE B 40

7 BOTULINUM TOXIN MARKET, BY APPLICATION

7.1 INTRODUCTION 41

7.2 THERAPEUTIC 42

7.2.1 CHRONIC MIGRAINE 43

7.2.2 SPASTICITY 44

7.2.3 CERVICAL DYSTONIA 44

7.2.4 OVERACTIVE BLADDER 44

7.2.5 BLEPHAROSPASM 45

7.2.6 OTHERS 45

7.3 AESTHETICS 45

8 BOTULINUM TOXIN MARKET, BY END USER

8.1 INTRODUCTION 47

8.2 DERMATOLOGY CENTRES 48

8.3 HOSPITALS & CLINICS 49

8.4 OTHERS 50

9 GLOBAL BOTULINUM TOXIN MARKET, BY REGION

9.1 INTRODUCTION 51

9.2 AMERICAS 52

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.2.1 NORTH AMERICA 56

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.2.1.1 US 58

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.2.1.2 CANADA 59

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.2.2 LATIN AMERICA 60

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3 EUROPE 62

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1 WESTERN EUROPE 65

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1.1 GERMANY 67

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1.2 UK 68

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1.3 ITALY 70

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1.4 FRANCE 71

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1.5 SPAIN 72

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.1.6 REST OF WESTERN EUROPE 74

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.3.2 EASTERN EUROPE 75

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4 ASIA-PACIFIC 77

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4.1 OVERVIEW 77

9.4.2 JAPAN 80

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4.3 CHINA 81

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4.4 SOUTH KOREA 82

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4.5 INDIA 84

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4.6 AUSTRALIA 85

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.4.7 REST OF ASIA-PACIFIC 86

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.5 MIDDLE EAST & AFRICA 88

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.5.1 MIDDLE EAST 90

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

9.5.2 AFRICA 92

BOTULINUM TOXIN MARKET, BY TYPE

BOTULINUM TOXIN MARKET, BY APPLICATION

BOTULINUM TOXIN MARKET, BY END USER

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW 94

10.2 COMPETITIVE BENCHMARKING 95

10.3 COMPETITOR DASHBOARD 96

10.4 GLOBAL BOTULINUM TOXIN MARKET: MAJOR PLAYERS 97

10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL BOTULINUM TOXIN MARKET 98

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 98

10.6.1 NEW PRODUCT LAUNCH/APPROVAL 98

10.6.2 JOINT VENTURE/COLLABORATION/PARTNERSHIP/AGREEMENT 99

10.6.3 EXPANSION 99

11 COMPANY PROFILES

11.1 ALLERGAN 100

11.1.1 COMPANY OVERVIEW 100

11.1.2 FINANCIAL OVERVIEW 101

11.1.3 PRODUCTS/SERVICES OFFERED 101

11.1.4 ALLERGAN: KEY DEVELOPMENTS 102

11.1.5 SWOT ANALYSIS 102

11.1.6 KEY STRATEGIES 102

11.2 MERZ PHARMA GMBH & CO. KGAA 103

11.2.1 COMPANY OVERVIEW 103

11.2.2 FINANCIAL OVERVIEW 104

11.2.3 PRODUCTS/SERVICES OFFERED 104

11.2.4 KEY DEVELOPMENTS 105

11.2.5 SWOT ANALYSIS 105

11.2.6 KEY STRATEGIES 105

11.3 GALDERMA SA 106

11.3.1 COMPANY OVERVIEW 106

11.3.2 FINANCIAL OVERVIEW 106

11.3.3 PRODUCTS/SERVICES OFFERED 107

11.3.4 KEY DEVELOPMENTS 108

11.3.5 SWOT ANALYSIS 108

11.3.6 KEY STRATEGIES 108

11.4 DAEWOONG PHARMACEUTICAL CO., LTD 109

11.4.1 COMPANY OVERVIEW 109

11.4.2 FINANCIAL OVERVIEW 110

11.4.3 PRODUCTS/SERVICES OFFERED 110

11.4.4 KEY DEVELOPMENTS 111

11.4.5 SWOT ANALYSIS 111

11.4.6 KEY STRATEGIES 111

11.5 IPSEN PHARMA 112

11.5.1 COMPANY OVERVIEW 112

11.5.2 FINANCIAL OVERVIEW 113

11.5.3 PRODUCTS/SERVICES OFFERED 113

11.5.4 KEY DEVELOPMENTS 114

11.5.5 SWOT ANALYSIS 114

11.5.6 KEY STRATEGIES 114

11.6 US WORLDMEDS, LLC (SOLSTICE NEUROSCIENCES, LLC) 115

11.6.1 COMPANY OVERVIEW 115

11.6.2 FINANCIAL OVERVIEW 115

11.6.3 PRODUCTS/SERVICES OFFERED 115

11.6.4 KEY DEVELOPMENTS 115

11.6.5 SWOT ANALYSIS 116

11.6.6 KEY STRATEGIES 116

11.7 EVOLUS, INC. 117

11.7.1 COMPANY OVERVIEW 117

11.7.2 EVOLUS, INC.: FINANCIAL OVERVIEW 117

11.7.3 PRODUCTS/SERVICES OFFERED 118

11.7.4 KEY DEVELOPMENTS 118

11.7.5 SWOT ANALYSIS 118

11.7.6 KEY STRATEGIES 118

11.8 HUGEL, INC. 119

11.8.1 COMPANY OVERVIEW 119

11.8.2 FINANCIAL OVERVIEW 120

11.8.3 PRODUCTS/SERVICES OFFERED 121

11.8.4 KEY DEVELOPMENTS 121

11.8.5 SWOT ANALYSIS 121

11.8.6 KEY STRATEGIES 121

11.9 MEDYTOX 122

11.9.1 COMPANY OVERVIEW 122

11.9.2 FINANCIAL OVERVIEW 122

11.9.3 PRODUCTS/SERVICES OFFERED 122

11.9.4 KEY DEVELOPMENTS 122

11.9.5 SWOT ANALYSIS 123

11.9.6 KEY STRATEGIES 123

11.10 REVANCE THERAPEUTICS, INC. 124

11.10.1 COMPANY OVERVIEW 124

11.10.2 FINANCIAL OVERVIEW 124

11.10.3 PRODUCTS/SERVICES OFFERED 125

11.10.4 KEY DEVELOPMENTS 125

11.10.5 SWOT ANALYSIS 126

11.10.6 KEY STRATEGIES 126

12 APPENDIX

12.1 REFERENCES 127

12.2 RELATED REPORTS 127

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 17

TABLE 2 PORTER’S FIVE FORCES ANALYSIS: GLOBAL BOTULINUM TOXIN MARKET 34

TABLE 3 GLOBAL BOTULINUM TOXIN MARKET, BY TYPE 2020-2027 (USD MILLION) 39

TABLE 4 GLOBAL BOTULINUM TOXIN MARKET, FOR BOTULINUM TOXIN TYPE A, BY REGION 2020-2027 (USD MILLION) 40

TABLE 5 GLOBAL BOTULINUM TOXIN MARKET, FOR BOTULINUM TOXIN TYPE B, BY REGION 2020-2027 (USD MILLION) 40

TABLE 6 GLOBAL BOTULINUM TOXIN MARKET, BY APPLICATION 2020-2027 (USD MILLION) 42

TABLE 7 GLOBAL BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY REGION 2020-2027 (USD MILLION) 42

TABLE 8 GLOBAL BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 43

TABLE 9 GLOBAL BOTULINUM TOXIN MARKET, FOR CHRONIC MIGRAINE, BY REGION 2020-2027 (USD MILLION) 43

TABLE 10 GLOBAL BOTULINUM TOXIN MARKET, FOR SPASTICITY, BY REGION 2020-2027 (USD MILLION) 44

TABLE 11 GLOBAL BOTULINUM TOXIN MARKET, FOR CERVICAL DYSTONIA, BY REGION 2020-2027 (USD MILLION) 44

TABLE 12 GLOBAL BOTULINUM TOXIN MARKET, FOR OVERACTIVE BLADDER, BY REGION 2020-2027 (USD MILLION) 44

TABLE 13 GLOBAL BOTULINUM TOXIN MARKET, FOR BLEPHAROSPASM, BY REGION 2020-2027 (USD MILLION) 45

TABLE 14 GLOBAL BOTULINUM TOXIN MARKET, FOR OTHERS, BY REGION 2020-2027 (USD MILLION) 45

TABLE 15 GLOBAL BOTULINUM TOXIN MARKET, FOR AESTHETICS, BY REGION 2020-2027 (USD MILLION) 46

TABLE 16 GLOBAL BOTULINUM TOXIN MARKET, BY END USER 2020-2027 (USD MILLION) 48

TABLE 17 GLOBAL BOTULINUM TOXIN MARKET, FOR DERMATOLOGY CENTRES, BY REGION 2020-2027 (USD MILLION) 49

TABLE 18 GLOBAL BOTULINUM TOXIN MARKET, FOR HOSPITALS & CLINICS, BY REGION 2020-2027 (USD MILLION) 49

TABLE 19 GLOBAL BOTULINUM TOXIN MARKET, FOR OTHER END USER, BY REGION 2020-2027 (USD MILLION) 50

TABLE 20 AMERICAS: BOTULINUM TOXIN MARKET, BY REGION, 2020–2027 (USD MILLION) 54

TABLE 21 AMERICAS: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 22 AMERICAS: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 54

TABLE 23 AMERICAS BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 55

TABLE 24 AMERICAS: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 55

TABLE 25 NORTH AMERICA: BOTULINUM TOXIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 56

TABLE 26 NORTH AMERICA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 27 NORTH AMERICA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 57

TABLE 28 NORTH AMERICA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 57

TABLE 29 NORTH AMERICA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 57

TABLE 30 US: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 31 US: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 58

TABLE 32 US BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 58

TABLE 33 US: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 34 CANADA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 35 CANADA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 59

TABLE 36 CANADA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 60

TABLE 37 CANADA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 38 LATIN AMERICA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 39 LATIN AMERICA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 61

TABLE 40 LATIN AMERICA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 61

TABLE 41 LATIN AMERICA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 42 EUROPE BOTULINUM TOXIN MARKET, BY REGION 2020-2027 (USD MILLION) 63

TABLE 43 EUROPE: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 44 EUROPE: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 64

TABLE 45 EUROPE BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 64

TABLE 46 EUROPE: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 47 WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY COUNTRY 2020-2027 (USD MILLION) 65

TABLE 48 WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 49 WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 66

TABLE 50 WESTERN EUROPEBOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 66

TABLE 51 WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 52 GERMANY: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 53 GERMANY: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 67

TABLE 54 GERMANY BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 68

TABLE 55 GERMANY: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 56 UK: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 57 UK: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 69

TABLE 58 UK BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 69

TABLE 59 UK: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 60 ITALY: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 61 ITALY: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 70

TABLE 62 ITALY BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 70

TABLE 63 ITALY: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 64 FRANCE: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 65 FRANCE: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 71

TABLE 66 FRANCE BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 72

TABLE 67 FRANCE: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 68 SPAIN: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 69 SPAIN: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 73

TABLE 70 SPAIN BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 73

TABLE 71 SPAIN: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 72 REST OF WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 73 REST OF WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 74

TABLE 74 REST OF WESTERN EUROPE BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 74

TABLE 75 REST OF WESTERN EUROPE: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 76 EASTERN EUROPE: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 77 EASTERN EUROPE: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 75

TABLE 78 EASTERN EUROPE BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 76

TABLE 79 EASTERN EUROPE: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 76

TABLE 80 ASIA-PACIFIC: BOTULINUM TOXIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78

TABLE 81 ASIA-PACIFIC: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 82 ASIA-PACIFIC: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 79

TABLE 83 ASIA-PACIFIC BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 79

TABLE 84 ASIA-PACIFIC: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 79

TABLE 85 JAPAN: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 86 JAPAN: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 80

TABLE 87 JAPAN BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 80

TABLE 88 JAPAN: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 81

TABLE 89 CHINA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 90 CHINA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81

TABLE 91 CHINA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 82

TABLE 92 CHINA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 93 SOUTH KOREA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 94 SOUTH KOREA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 83

TABLE 95 SOUTH KOREA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 83

TABLE 96 SOUTH KOREA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 83

TABLE 97 INDIA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 98 INDIA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84

TABLE 99 INDIA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 84

TABLE 100 INDIA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 101 AUSTRALIA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 102 AUSTRALIA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85

TABLE 103 AUSTRALIA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 86

TABLE 104 AUSTRALIA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 86

TABLE 105 REST OF ASIA PACIFIC: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 106 REST OF ASIA PACIFIC: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 87

TABLE 107 REST OF ASIA PACIFIC BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 87

TABLE 108 REST OF ASIA PACIFIC: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 87

TABLE 109 MIDDLE EAST & AFRICA: BOTULINUM TOXIN MARKET, BY REGION, 2020–2027 (USD MILLION) 89

TABLE 110 MIDDLE EAST & AFRICA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 111 MIDDLE EAST & AFRICA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89

TABLE 112 MIDDLE EAST & AFRICA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 90

TABLE 113 MIDDLE EAST & AFRICA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 90

TABLE 114 MIDDLE EAST: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 115 MIDDLE EAST: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91

TABLE 116 MIDDLE EAST BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 91

TABLE 117 MIDDLE EAST: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 91

TABLE 118 AFRICA: BOTULINUM TOXIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 119 AFRICA: BOTULINUM TOXIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92

TABLE 120 AFRICA BOTULINUM TOXIN MARKET, FOR THERAPEUTIC, BY TYPE 2020-2027 (USD MILLION) 92

TABLE 121 AFRICA: BOTULINUM TOXIN MARKET, BY END USER, 2020–2027 (USD MILLION) 93

TABLE 122 THE MOST ACTIVE PLAYER IN THE GLOBAL BOTULINUM TOXIN MARKET 98

TABLE 123 NEW PRODUCT LAUNCH/APPROVAL 98

TABLE 124 JOINT VENTURE 99

TABLE 125 EXPANSION 99

TABLE 126 ALLERGAN: PRODUCTS/SERVICES OFFERED 101

TABLE 127 KEY DEVELOPMENTS 102

TABLE 128 MERZ PHARMA GMBH & CO. KGAA: PRODUCTS/SERVICES OFFERED 104

TABLE 129 MERZ PHARMA GMBH & CO. KGAA: KEY DEVELOPMENTS 105

TABLE 130 GALDERMA SA: PRODUCTS/SERVICES OFFERED 107

TABLE 131 GALDERMA SA: KEY DEVELOPMENTS 108

TABLE 132 DAEWOONG PHARMACEUTICAL CO., LTD: PRODUCTS/SERVICES OFFERED 110

TABLE 133 DAEWOONG PHARMACEUTICAL CO., LTD: KEY DEVELOPMENTS 111

TABLE 134 IPSEN PHARMA: PRODUCTS/SERVICES OFFERED 113

TABLE 135 IPSEN PHARMA: KEY DEVELOPMENTS 114

TABLE 136 US WORLDMEDS, LLC: PRODUCTS/SERVICES OFFERED 115

TABLE 137 US WORLDMEDS, LLC.: KEY DEVELOPMENTS 115

TABLE 138 EVOLUS, INC.: PRODUCTS/SERVICES OFFERED 118

TABLE 139 HUGEL, INC.: PRODUCTS/SERVICES OFFERED 121

TABLE 140 MEDYTOX: PRODUCTS/SERVICES OFFERED 122

TABLE 141 MEDYTOX: KEY DEVELOPMENTS 122

TABLE 142 REVANCE THERAPEUTICS, INC.: PRODUCT PIPELINE 125

TABLE 143 REVANCE THERAPEUTICS, INC.: KEY DEVELOPMENTS 125

14 LIST OF FIGURES

FIGURE 1 GLOBAL BOTULINUM TOXIN MARKET: MARKET STRUCTURE 18

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 25

FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL BOTULINUM TOXIN MARKET 28

FIGURE 4 DRIVER IMPACT ANALYSIS 31

FIGURE 5 RESTRAINT IMPACT ANALYSIS 32

FIGURE 6 VALUE CHAIN: GLOBAL BOTULINUM TOXIN MARKET 36

FIGURE 7 GLOBAL BOTULINUM TOXIN MARKET SHARE, BY TYPE 2020 (%) 38

FIGURE 8 GLOBAL BOTULINUM TOXIN MARKET, BY TYPE 2020 & 2027 (USD MILLION) 39

FIGURE 9 GLOBAL BOTULINUM TOXIN MARKET SHARE, BY APPLICATION 2020 (%) 41

FIGURE 10 GLOBAL BOTULINUM TOXIN MARKET, BY APPLICATION2020 & 2027 (USD MILLION) 42

FIGURE 11 GLOBAL BOTULINUM TOXIN MARKET SHARE, BY END USER 2020 (%) 47

FIGURE 12 GLOBAL BOTULINUM TOXIN MARKET, BY END USER 2020 & 2027 (USD MILLION) 48

FIGURE 13 GLOBAL BOTULINUM TOXIN MARKET SHARE, BY REGION 2020 (%) 51

FIGURE 14 GLOBAL BOTULINUM TOXIN MARKET SHARE, BY REGION 2020 & 2027 (USD MILLION) 52

FIGURE 15 AMERICAS BOTULINUM TOXIN MARKET SHARE, BY REGION 2020 (%) 53

FIGURE 16 AMERICAS BOTULINUM TOXIN MARKET, BY REGION 2020 & 2027 (USD MILLION) 53

FIGURE 17 NORTH AMERICA BOTULINUM TOXIN MARKET SHARE, BY COUNTRY 2020 (%) 56

FIGURE 18 EUROPE BOTULINUM TOXIN MARKET SHARE, BY REGION 2020 (%) 62

FIGURE 19 EUROPE BOTULINUM TOXIN MARKET, BY REGION 2020 & 2027 (USD MILLION) 63

FIGURE 20 WESTERN EUROPE BOTULINUM TOXIN MARKET SHARE, BY COUNTRY 2020 (%) 65

FIGURE 21 ASIA-PACIFIC BOTULINUM TOXIN MARKET SHARE, BY COUNTRY2020 (%) 77

FIGURE 22 ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY 2020 & 2027 (USD MILLION) 78

FIGURE 23 MIDDLE EAST & AFRICA BOTULINUM TOXIN MARKET SHARE, BY REGION 2020 (%) 88

FIGURE 24 MIDDLE EAST & AFRICA BOTULINUM TOXIN MARKET, BY REGION 2020 & 2027 (USD MILLION) 88

FIGURE 25 BENCHMARKING OF MAJOR COMPETITORS 95

FIGURE 26 COMPETITOR DASHBOARD: GLOBAL BOTULINUM TOXIN MARKET 96

FIGURE 27 MAJOR MANUFACTURERS: GLOBAL BOTULINUM TOXIN MARKET, 2020 97

FIGURE 28 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT 101

FIGURE 29 ALLERGAN: SWOT ANALYSIS 102

FIGURE 30 MERZ PHARMA GMBH & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT 104

FIGURE 31 MERZ PHARMA GMBH & CO. KGAA: SWOT ANALYSIS 105

FIGURE 32 NESTLÉ: FINANCIAL OVERVIEW SNAPSHOT 107

FIGURE 33 GALDERMA SA: SWOT ANALYSIS 108

FIGURE 34 DAEWOONG PHARMACEUTICAL CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 110

FIGURE 35 DAEWOONG PHARMACEUTICAL CO., LTD: SWOT ANALYSIS 111

FIGURE 36 IPSEN PHARMA: FINANCIAL OVERVIEW SNAPSHOT 113

FIGURE 37 IPSEN PHARMA: SWOT ANALYSIS 114

FIGURE 38 US WORLDMEDS, LLC: SWOT ANALYSIS 116

FIGURE 39 EVOLUS, INC.: SWOT ANALYSIS 118

FIGURE 40 HUGEL, INC.: FINANCIAL OVERVIEW SNAPSHOT 120

FIGURE 41 HUGEL, INC.: SWOT ANALYSIS 121

FIGURE 42 MEDYTOX: SWOT ANALYSIS 123

FIGURE 43 REVANCE THERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT 124

FIGURE 44 REVANCE THERAPEUTICS, INC.: SWOT ANALYSIS 126